{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:49:53Z","timestamp":1776826193883,"version":"3.51.2"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41397-026-00402-8","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T11:40:21Z","timestamp":1773402021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A potential association of SLC2A9 variant rs7442295 with uric acid at baseline and in interaction with iloperidone"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8006-0454","authenticated-orcid":false,"given":"Sandra P.","family":"Smieszek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2424-7983","authenticated-orcid":false,"given":"Sean R.","family":"Chadwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily L.","family":"Czeisler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosarelis","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2833-0813","authenticated-orcid":false,"given":"Haimeng","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changfu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos M.","family":"Polymeropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunther","family":"Birznieks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihael H.","family":"Polymeropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"402_CR1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","volume":"375","author":"P Richette","year":"2010","unstructured":"Richette P, Bardin T. Gout. Lancet. 2010;375:318\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(09)60883-7","journal-title":"Lancet"},{"key":"402_CR2","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.3949\/ccjm.75.suppl_5.s5","volume":"75","author":"BF Mandell","year":"2008","unstructured":"Mandell BF. Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med. 2008;75:S5\u20138. https:\/\/doi.org\/10.3949\/ccjm.75.suppl_5.s5","journal-title":"Cleve Clin J Med"},{"key":"402_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0878-5","volume":"15","author":"N Dalbeth","year":"2017","unstructured":"Dalbeth N, Stamp LK, Merriman TR. The genetics of gout: Towards personalised medicine? BMC Med. 2017;15:108 https:\/\/doi.org\/10.1186\/s12916-017-0878-5","journal-title":"BMC Med"},{"key":"402_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.667753","volume":"12","author":"HL Sun","year":"2021","unstructured":"Sun HL, Wu YW, Bian HG, Yang H, Wang H, Meng XM, et al. Function of Uric Acid Transporters and Their Inhibitors in Hyperuricaemia. Front Pharmacol. 2021;12:667753 https:\/\/doi.org\/10.3389\/fphar.2021.667753","journal-title":"Front Pharmacol"},{"key":"402_CR5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/rheumatology\/kew293","volume":"56","author":"C Ben Salem","year":"2017","unstructured":"Ben Salem C, Slim R, Fathallah N, Hmouda H. Drug-induced hyperuricaemia and gout. Rheumatology (Oxford). 2017;56:679\u201388. https:\/\/doi.org\/10.1093\/rheumatology\/kew293","journal-title":"Rheumatology (Oxford)"},{"key":"402_CR6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.5457","volume":"11","author":"R Raja","year":"2019","unstructured":"Raja R, Kavita F, Amreek F, Shah A, Sayeed KA, Sehar A. Hyperuricemia Associated with Thiazide Diuretics in Hypertensive Adults. Cureus. 2019;11:e5457 https:\/\/doi.org\/10.7759\/cureus.5457","journal-title":"Cureus"},{"key":"402_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5049\/EBP.2021.19.1.1","volume":"19","author":"S Chung","year":"2021","unstructured":"Chung S, Kim GH. Urate Transporters in the Kidney: What Clinicians Need to Know. Electrolyte Blood Press. 2021;19:1\u20139. https:\/\/doi.org\/10.5049\/EBP.2021.19.1.1","journal-title":"Electrolyte Blood Press"},{"key":"402_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/ng.2500","volume":"45","author":"A K\u00f6ttgen","year":"2013","unstructured":"K\u00f6ttgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet. 2013;45:145\u201354. https:\/\/doi.org\/10.1038\/ng.2500","journal-title":"Nat Genet"},{"key":"402_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27198-4","volume":"12","author":"A Tin","year":"2021","unstructured":"Tin A, Schlosser P, Matias-Garcia PR, Thio CHL, Joehanes R, Liu H, et al. Epigenome-wide association study of serum urate reveals insights into urate co-regulation and the SLC2A9 locus. Nat Commun. 2021;12:7173 https:\/\/doi.org\/10.1038\/s41467-021-27198-4","journal-title":"Nat Commun"},{"key":"402_CR10","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.34067\/KID.0007552021","volume":"3","author":"AW Aron","year":"2022","unstructured":"Aron AW, Dahl NK, Besse W. A Practical Guide to Genetic Testing for Kidney Disorders of Unknown Etiology. Kidney360. 2022;3:1640\u20133. https:\/\/doi.org\/10.34067\/KID.0007552021","journal-title":"Kidney360"},{"key":"402_CR11","first-page":"3167","volume":"12","author":"L Li","year":"2020","unstructured":"Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am J Transl Res. 2020;12:3167\u201381. PMID: 32774692","journal-title":"Am J Transl Res"},{"key":"402_CR12","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1176\/appi.ajp.2007.06111932","volume":"164","author":"M Tohen","year":"2007","unstructured":"Tohen M, Kryzhanovskaya L, Carlson G, DelBello M, Wozniak J, Kowatch R, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007;164:1547\u201356. https:\/\/doi.org\/10.1176\/appi.ajp.2007.06111932","journal-title":"Am J Psychiatry"},{"key":"402_CR13","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.4088\/JCP.v69n1113","volume":"69","author":"M Tohen","year":"2008","unstructured":"Tohen M, Vieta E, Goodwin GM, Sun B, Amsterdam JD, Banov M, et al. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry. 2008;69:1776\u201389. https:\/\/doi.org\/10.4088\/JCP.v69n1113","journal-title":"J Clin Psychiatry"},{"key":"402_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/CHI.0b013e3181900404","volume":"48","author":"L Kryzhanovskaya","year":"2009","unstructured":"Kryzhanovskaya L, Schulz SC, McDougle C, Frazier J, Dittmann R, Robertson-Plouch C, et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48:60\u201370. https:\/\/doi.org\/10.1097\/CHI.0b013e3181900404","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"402_CR15","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3389\/fphar.2016.00527","volume":"7","author":"N Vanwong","year":"2016","unstructured":"Vanwong N, Srisawasdi P, Ngamsamut N, Nuntamool N, Puangpetch A, Chamkrachangpada B, et al. Hyperuricemia in Children and Adolescents with Autism Spectrum Disorder Treated with Risperidone: The Risk Factors for Metabolic Adverse Effects. Front Pharmacol. 2016;7:527 https:\/\/doi.org\/10.3389\/fphar.2016.00527","journal-title":"Front Pharmacol"},{"key":"402_CR16","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1097\/JCP.0b013e318169d4ce","volume":"28","author":"AJ Cutler","year":"2008","unstructured":"Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28:S20\u2013S28. https:\/\/doi.org\/10.1097\/JCP.0b013e318169d4ce","journal-title":"J Clin Psychopharmacol"},{"key":"402_CR17","doi-asserted-by":"publisher","first-page":"23m14966","DOI":"10.4088\/JCP.23m14966","volume":"85","author":"R Torres","year":"2024","unstructured":"Torres R, Czeisler EL, Chadwick SR, Stahl SM, Smieszek SP, Xiao C, et al. Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study. J Clin Psychiatry. 2024;85:23m14966 https:\/\/doi.org\/10.4088\/JCP.23m14966","journal-title":"J Clin Psychiatry"},{"key":"402_CR18","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1192\/bjp.bp.114.152249","volume":"205","author":"L Forty","year":"2014","unstructured":"Forty L, Ulanova A, Jones L, Jones I, Gordon-Smith K, Fraser C, et al. Comorbid medical illness in bipolar disorder. Br J Psychiatry. 2014;205:465\u201372. https:\/\/doi.org\/10.1192\/bjp.bp.114.152249","journal-title":"Br J Psychiatry"},{"key":"402_CR19","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/ng.107","volume":"40","author":"A D\u00f6ring","year":"2008","unstructured":"D\u00f6ring A, Gieger C, Mehta D, Gohlke H, Prokisch H, Coassin S, et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet. 2008;40:430\u20136. https:\/\/doi.org\/10.1038\/ng.107","journal-title":"Nat Genet"},{"key":"402_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1268226","volume":"11","author":"S Wu","year":"2023","unstructured":"Wu S, Li C, Li Y, Liu J, Rong C, Pei H, et al. SLC2A9 rs16890979 reduces uric acid absorption by kidney organoids. Front Cell Dev Biol. 2023;11:1268226 https:\/\/doi.org\/10.3389\/fcell.2023.1268226","journal-title":"Front Cell Dev Biol"},{"key":"402_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96959-4","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang Y, Charchar FJ. Establishment of sex difference in circulating uric acid is associated with higher testosterone and lower sex hormone-binding globulin in adolescent boys. Sci Rep. 2021;11:16983 https:\/\/doi.org\/10.1038\/s41598-021-96959-4","journal-title":"Sci Rep"},{"key":"402_CR22","unstructured":"George C, Leslie SW, Minter DA. Hyperuricemia. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459218\/"},{"key":"402_CR23","unstructured":"Vanda Pharmaceuticals Inc. Fanapt (iloperidone) tablets [package insert]. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/022192s023lbl.pdf"},{"key":"402_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ajhg.2007.11.001","volume":"82","author":"C Wallace","year":"2008","unstructured":"Wallace C, Newhouse SJ, Braund P, Zhang F, Tobin M, Falchi M, et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. The American Journal of Human Genetics. 2008;82:139\u201349. https:\/\/doi.org\/10.1016\/j.ajhg.2007.11.001","journal-title":"The American Journal of Human Genetics"},{"key":"402_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17:122 https:\/\/doi.org\/10.1186\/s13059-016-0974-4","journal-title":"Genome Biol"},{"key":"402_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1093\/bioinformatics\/btz502","volume":"36","author":"J Wang","year":"2020","unstructured":"Wang J, Youkharibache P, Zhang D, Lanczycki CJ, Geer RC, Madej T, et al. iCn3D, a web-based 3D viewer for sharing 1D\/2D\/3D representations of biomolecular structures. Bioinformatics. 2020;36:131\u20135. https:\/\/doi.org\/10.1093\/bioinformatics\/btz502","journal-title":"Bioinformatics"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00402-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00402-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00402-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:18:37Z","timestamp":1776824317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00402-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["402"],"URL":"https:\/\/doi.org\/10.1038\/s41397-026-00402-8","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"13 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors are employees of Vanda Pharmaceuticals Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocols and all amendments were reviewed by the Independent Ethics Committee or Institutional Review Board for each center in each study. The studies from which samples were obtained was conducted according to the ethical principles of the Declaration of Helsinki and all methods were carried out in accordance with relevant guidelines and regulations. Informed consent was obtained from all participants and\/or their legal guardian in writing before any study-specific procedures were performed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The sponsor was responsible for the design, analysis, interpretation, and publication of the clinical trials. Final approval for the decisions to submit the manuscript was the sole decision of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the sponsor"}},{"value":"Drs Smieszek, Chadwick, Bai, Torres, Xiao, C. Polymeropoulos, M. Polymeropoulos, Mr Birznieks and Ms Czeisler are full time employees of Vanda Pharmaceuticals Inc. and may hold company stock and\/or stock options.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Relevant financial relationships"}}],"article-number":"10"}}